Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

GW Pharmaceuticals data the "most convincing so far", says City heavyweight

Earlier this month investors were put on bid alert after a report suggest the company had multiple potential suitors.
GW Pharmaceuticals data the "most convincing so far", says City heavyweight
GW is a specialist in cannabis-derived medicines.

“Impressive so far”, is the verdict of one leading City broker, referring to the progress of GW Pharmaceuticals PLC (LON:GWP, NASDAQ:GWPH) and the results from its lead drug for a childhood epilepsy.

Numis, in a note, repeated its 835p valuation of stock in the druggie, which is at the cutting edge of cannabis-derived medicines.

The shares ended the week at 838.5p, up 20%.

The driver? GW unveiled more pointers to the efficacy of Epidolex, for childhood seizures.

Numis analyst Paul Cuddon called it “the most convincing ”data so far.

It is expected GW will make a new drug application early next year.

Earlier this month investors were put on bid alert after a report suggest the company had multiple potential suitors.

The Reuters story also said GW had appointed Wall Street heavyweight Morgan Stanley to oversee the potential beauty parade.

The interest was very firmly rooted around Epidiolex, which analysts reckon has the potential to deliver annual sales of around US$800mln.

The identities of the potential suitors were unknown.

However, the big beasts in this sphere of the drugs market are Novartis (ETX:NOVN), Bayer (ETR:BAYN) and Almirall (BME:ALM).

Numis, in an earlier broker note, reckoned Lundbeck (CPH:LUN), Otsuka (TYO:4578) and Biogen (NASDAQ:BIIB) might also be in the running.

In the year to date the stock has advanced 102%, buoyed by some encouraging headline results from a phase III clinical trial of Epidiolex.

On the back of that the company was able to raise £190mln from US investors to bankroll the further development of its lead product.

Valued at £2.4bn, GW is AIM’s third largest company.

View full GWP profile View Profile

GW Pharmaceuticals Timeline

Related Articles

bacteria
June 27 2018
Ridinilazole is a possible treatment for C. Difficile and Summit hopes to kick off a phase III trial in the first quarter of 2019
Callitas CEO James Thompson
Fri
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
1528098797_Biotech-lab.jpg
June 04 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use